Dr. Nastoupil on Questions Surrounding TGR1202 in Patients With CLL

Loretta J. Nastoupil, MD
Published: Monday, Aug 21, 2017



Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the questions researchers are currently facing with TGR1202 in patients with chronic lymphocytic leukemia (CLL).

This was a phase I study with a small cohort of patients with CLL; however, it did include a long duration of drug exposure. Prior data with PI3K inhibitors show that it is associated with unique side effects, such as infection, pneumonitis, transaminitis, and colitis that have impeded patients' ability to stay on therapy.

However, TGR1202 may have a differentiated safety profile. There have not been the same rates of adverse events observed. However, there was an 18% rate of neutropenia, which compares favorably with chemotherapy. Additionally, there was an 11% of pneumonia favorable across comparison with other PI3K inhibitors. Longer follow-up is needed, she concludes.


Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the questions researchers are currently facing with TGR1202 in patients with chronic lymphocytic leukemia (CLL).

This was a phase I study with a small cohort of patients with CLL; however, it did include a long duration of drug exposure. Prior data with PI3K inhibitors show that it is associated with unique side effects, such as infection, pneumonitis, transaminitis, and colitis that have impeded patients' ability to stay on therapy.

However, TGR1202 may have a differentiated safety profile. There have not been the same rates of adverse events observed. However, there was an 18% rate of neutropenia, which compares favorably with chemotherapy. Additionally, there was an 11% of pneumonia favorable across comparison with other PI3K inhibitors. Longer follow-up is needed, she concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x